Reports
Through its enabling statute, the Prescription Drug Affordability Board is required to study the entire pharmaceutical distribution and payment system in Maryland and the policy options being used in other states and countries to lower the list price of pharmaceuticals. This includes setting upper payment limits, using reverse auction marketplaces, and implementing a bulk purchasing process. Following its study, the Board will publish a report on its findings and recommendations, including any necessary legislative action.
Draft Working Document: Supply Chain Report- Health- General Art.§ 21-2C-07 is now posted and the PDAB will be accepting comments on this document until close of business 1/10/2024. Comments may be sent to comments.pdab@maryland.gov
December 31, 2023 - 2023 Health General Article § 21-2C-09- Cost Review Report
December 31, 2022 - 2022 Health General Article § 21-2C-09- Cost Review Report
June 1, 2022 - Study of the Operation of the Generics Drug Market
Completed under the authority of 2019 Maryland Laws Ch. 692, § 5 (uncodified) (H.B. 768), as amended by 2020 Maryland Laws Ch. 425, this one-time study reviews physician-administered drugs, the prices of generic drugs on a year–over–year basis, the degree to which generic drug prices affect yearly insurance premium changes, annual changes in insurance cost–sharing for generic drugs, the potential for and history of drug shortages, and the degree to which generic drug prices affect yearly State Medicaid spending.
Please contact support.pdab@maryland.gov with any questions.
The Board is also charged with conducting and reporting a study on the operation of the generic drug market in the United States, including change in prices, the effect on premiums, and the potential for shortages.